fludarabine + cyclophosphamide + CD7-specific CAR-T cells

Fludarabine + cyclophosphamide + CD7-specific CAR-T cells is a combination therapy used primarily in the treatment of T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). Fludarabine and cyclophosphamide are chemotherapeutic agents commonly used as a lymphodepleting preconditioning regimen to reduce the patient’s existing immune cells, thereby enhancing the engraftment and efficacy of subsequently infused CAR-T cells. The third component, CD7-specific chimeric antigen receptor (CAR) T cells, are genetically engineered autologous or allogeneic T lymphocytes that express a synthetic receptor targeting the CD7 antigen present on malignant T-cells. The mechanism of action involves direct cytotoxicity against CD7-expressing tumor cells through recognition by the engineered CAR, leading to tumor cell lysis via cytokine secretion and cytolytic granule release. This approach aims to achieve potent anti-leukemic effects while overcoming challenges such as fratricide among CAR-T products by using strategies like downregulation or editing of endogenous CD7 expression in therapeutic T-cells[1][2][4][5].

Other names

fludarabine + cyclophosphamide + CAR-T cellsfludarabine + cyclophosphamide + CAR7-T cells